Journal article
Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look.
Abstract
BACKGROUND: Biologics have changed the way we treat moderate to severe psoriasis. Clinical trials for these patients offer the chance for those suffering from psoriasis to volunteer their time for the advancement of science while possibly gaining benefit from the efficacy of these medications.
Authors
Vender RB
Journal
Journal of Drugs in Dermatology, Vol. 15, No. 8, pp. 941–943
Publication Date
August 1, 2016
ISSN
1545-9616